

Meifang Han

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3328720/publications.pdf>

Version: 2024-02-01

41
papers

8,335
citations

361413

20
h-index

302126

39
g-index

42
all docs

42
docs citations

42
times ranked

20315
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical and immunological features of severe and moderate coronavirus disease 2019. <i>Journal of Clinical Investigation</i> , 2020, 130, 2620-2629.	8.2	3,820
2	Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. <i>BMJ</i> , The, 2020, 368, m1091.	6.0	3,061
3	Acute liver failure: mechanisms of immune-mediated liver injury. <i>Liver International</i> , 2010, 30, 782-794.	3.9	218
4	Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: A randomised open-label trial (OSST trial). <i>Journal of Hepatology</i> , 2014, 61, 777-784.	3.7	198
5	Longitudinal changes of inflammatory parameters and their correlation with disease severity and outcomes in patients with COVID-19 from Wuhan, China. <i>Critical Care</i> , 2020, 24, 525.	5.8	125
6	Increased Killing of Liver NK Cells by Fas/Fas Ligand and NKG2D/NKG2D Ligand Contributes to Hepatocyte Necrosis in Virus-Induced Liver Failure. <i>Journal of Immunology</i> , 2010, 184, 466-475.	0.8	121
7	Role of Fibrinogen-Like Protein 2 Prothrombinase/Fibroleukin in Experimental and Human Allograft Rejection. <i>Journal of Immunology</i> , 2005, 174, 7403-7411.	0.8	63
8	Hepatitis B Virus-induced hFGL2 Transcription Is Dependent on c-Ets-2 and MAPK Signal Pathway. <i>Journal of Biological Chemistry</i> , 2008, 283, 32715-32729.	3.4	46
9	Sustained immune control in HBeAg-positive patients who switched from entecavir therapy to pegylated interferon- α 2a: 1-year follow-up of the OSST study. <i>Antiviral Therapy</i> , 2016, 21, 337-344.	1.0	37
10	Clinical characteristics and risk factors of liver injury in COVID-19: a retrospective cohort study from Wuhan, China. <i>Hepatology International</i> , 2020, 14, 723-732.	4.2	35
11	The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implication. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 57.	17.1	34
12	KCTD9 contributes to liver injury through NK cell activation during hepatitis B virus-induced acute-on-chronic liver failure. <i>Clinical Immunology</i> , 2013, 146, 207-216.	3.2	33
13	SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity. , 2020, 8, e000862.		33
14	Entecavir treatment prevents disease progression in hepatitis B virus-related acute-on-chronic liver failure: establishment of a novel logistical regression model. <i>Hepatology International</i> , 2012, 6, 735-743.	4.2	31
15	Immunological Characteristics in Type 2 Diabetes Mellitus Among COVID-19 Patients. <i>Frontiers in Endocrinology</i> , 2021, 12, 596518.	3.5	30
16	Sequential combination therapy with interferon, interleukin-2 and therapeutic vaccine in entecavir-suppressed chronic hepatitis B patients: the Endeavor study. <i>Hepatology International</i> , 2019, 13, 573-586.	4.2	29
17	The Nucleocapsid Protein of SARS-CoV Induces Transcription of hfgl2 Prothrombinase Gene Dependent on C/EBP Alpha. <i>Journal of Biochemistry</i> , 2008, 144, 51-62.	1.7	28
18	End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN-based therapy in patients with CHB. <i>Journal of Hepatology</i> , 2022, 77, 42-54.	3.7	28

#	ARTICLE	IF	CITATIONS
19	Nucleoside analogs prevent disease progression in HBV-related acute-on-chronic liver failure: validation of the TPPM model. <i>Hepatology International</i> , 2014, 8, 64-71.	4.2	27
20	IFN- λ -mediated Base Excision Repair Pathway Correlates with Antiviral Response Against Hepatitis B Virus Infection. <i>Scientific Reports</i> , 2017, 7, 12715.	3.3	25
21	Interferon-Induced Macrophage-Derived Exosomes Mediate Antiviral Activity Against Hepatitis B Virus Through miR-574-5p. <i>Journal of Infectious Diseases</i> , 2021, 223, 686-698.	4.0	24
22	Molecular epidemiology of hepatitis delta virus in the Western Pacific region. <i>Journal of Clinical Virology</i> , 2014, 61, 34-39.	3.1	23
23	Hepatitis B virus genotype B and mutations in basal core promoter and pre-core/core genes associated with acute-on-chronic liver failure: a multicenter cross-sectional study in China. <i>Hepatology International</i> , 2014, 8, 508-516.	4.2	18
24	An integration of deep viral suppression with sequential immune modulation (cocktail therapy) to restore antiviral capacity: The future of chronic hepatitis B?. <i>Journal of Hepatology</i> , 2015, 62, 240-241.	3.7	17
25	Functional restoration of CD56 ^{bright} NK cells facilitates immune control via IL-15 and NKG2D in patients under antiviral treatment for chronic hepatitis B. <i>Hepatology International</i> , 2017, 11, 419-428.	4.2	12
26	Altered expression of interferon-stimulated genes is strongly associated with therapeutic outcomes in hepatitis B virus infection. <i>Antiviral Research</i> , 2017, 147, 75-85.	4.1	11
27	Resistant mutations and quasispecies complexity of hepatitis B virus during telbivudine treatment. <i>Journal of General Virology</i> , 2015, 96, 3302-3312.	2.9	11
28	A disparate subset of double-negative T cells contributes to the outcome of murine fulminant viral hepatitis via effector molecule fibrinogen-like protein 2. <i>Immunologic Research</i> , 2016, 64, 518-530.	2.9	9
29	Pegylated Interferon- λ (IFN- λ) Enhances the Inhibitory Effect of Natural Killer Cells on Regulatory T Cells via IFN- λ in Chronic Hepatitis B. <i>Journal of Infectious Diseases</i> , 2021, 224, 1878-1889.	4.0	8
30	Interference with KCTD9 inhibits NK cell activation and ameliorates fulminant liver failure in mice. <i>BMC Immunology</i> , 2018, 19, 20.	2.2	7
31	Hepatitis B virus surface protein-induced <i>hPIAS1</i> transcription requires TAL1, E47, MYOG, NFI, and MAPK signal pathways. <i>Biological Chemistry</i> , 2016, 397, 1173-1185.	2.5	6
32	Superinfective Hepatitis E Virus Infection Aggravates Hepatocytes Injury in Chronic Hepatitis B. <i>Current Medical Science</i> , 2019, 39, 719-726.	1.8	6
33	Diagnostic thresholds and performance of noninvasive fibrosis scores are limited by age in patients with chronic hepatitis B. <i>Journal of Medical Virology</i> , 2019, 91, 1279-1287.	5.0	6
34	Clinical analysis and a novel risk predictive nomogram for 155 adult patients with hemophagocytic lymphohistiocytosis. <i>Annals of Hematology</i> , 2021, 100, 2181-2193.	1.8	6
35	Lower Serum Angiotensin-Converting Enzyme Level in Relation to Hyperinflammation and Impaired Antiviral Immune Response Contributes to Progression of COVID-19 Infection. <i>Infectious Diseases and Therapy</i> , 2021, 10, 2431-2446.	4.0	5
36	Plasma lipidomics identifies novel biomarkers in patients with hepatitis B virus-related acute-on-chronic liver failure. <i>Metabolomics</i> , 2017, 13, 1.	3.0	3

#	ARTICLE	IF	CITATIONS
37	Insufficient immunity led to virologic breakthrough in NAs-treated chronic hepatitis B patients switching to PegIFN. Antiviral Research, 2022, 197, 105220.	4.1	3
38	Hepatic exosomes with declined MiR-27b trigger RIGI/TBK1 signal pathway in macrophages. Liver International, 2022, 42, 1676-1691.	3.9	3
39	Antiviral resistance mutations potentiate HBV surface antigen-induced transcription of hfgl2 prothrombinase gene. Biochemistry (Moscow), 2011, 76, 1043-1050.	1.5	2
40	The potential immune regulation benefit of CpAMs beyond HBV suppression. The Lancet Gastroenterology and Hepatology, 2021, 6, 680-682.	8.1	2
41	Construction of plasmids expressing Sars-CoV encoding proteins and their effects on transcription of hfgl2 prothrombinase. Journal of Huazhong University of Science and Technology [Medical Sciences], 2009, 29, 318-323.	1.0	0